September 2024 | ASH Clinical News | American Society of Hematology September 2024 A Nickle Ain’t Worth a Dime Anymore NIH research funding doesn’t go as far as it used to, and researchers feel the pinch more every year. Viewpoints Editor’s Corner As a Professor of Medicine, I’m Proud to Say I’m Still Here Education You Make the Call You…
She’s still looking for 3-month-old Phoebe, nearly two weeks after the dog reportedly disappeared in Kissena Corridor Park.
Myelodysplastic syndromes/neoplasms (MDS) are a widely heterogenous group of myeloid malignancies characterized by morphologic dysplasia, a defective hemat
Measures introduced to support general practice – including greater use of remote consultations, digital triage and an expansion of additional roles – have had the…
Latest SunLife study shows average total funeral cost at £9,797 with many selling off possessions to help pay
Dr. Bertagnolli served as the 17th NIH Director.
The introduction of checkpoint inhibitor immunotherapy targeting programmed death-1 and programmed death-ligand 1 (PD-L1) has led to improved survival in patients with advanced non-small cell…
PURPOSETransurethral resection of bladder tumor (TURBT) is the initial staging procedure for new bladder cancers (BCs). For muscle-invasive bladder cancers (MIBCs), TURBT may delay definitive…
s within the historical context and direct patient care experience. Recent findings ECT is typically implemented for psychotropic-refractory catatonic, affective, psychotic, and combined pathology for…
ABSTRACT. Amyloidosis is a group of complex diseases caused by the misfolding and aggregation of proteins into amyloid fibrils. Light-chain (AL) amyloidosi
